Group items matching

in title, tags, annotations or url

The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed. Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent after more research in the coming weeks. "It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio. But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly." In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

The Pharmacists' Defence Association (PDA) has emerged as a key player in international humanitarian efforts, delivering millions of pounds worth of medical aid to disaster-hit regions. This marks a significant evolution for the PDA, which has embraced a leadership role in global relief initiatives. The PDA, a member of the Employed Pharmacists of Europe (EPhEU), responded to an urgent appeal from its Ukrainian members following the extensive damage to Ukraine's healthcare infrastructure during the military invasion. As the elected Secretary General of EPhEU, PDA Chairman Mark Koziol orchestrated a campaign encouraging public donations through 'Medicines to Ukraine' posters displayed in pharmacies across Europe. The campaign successfully raised over £4.5 million, which was used to procure and deliver essential medicines directly to Ukrainian Ministry of Health pharmacists.

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND. This extends the UK government's support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years. FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development. Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: "Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives."

Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise. The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa. Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England. Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last. But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people. "These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.

The UK Health Security Agency (UKHSA) said last week (Aug 5) there were "early signs" that the monkeypox outbreak was plateauing across the country and that its expansion had slowed. "While the most recent data suggests the growth of the outbreak has slowed, we cannot be complacent," Dr Meera Chand, director of clinical and emerging infections at UKHSA, said. There were 2,859 confirmed and highly probable cases of monkeypox in the UK as of Aug. 4, with nearly 99 per cent of the cases among men, the country's health authority said in a statement. The recent analysis by the UKHSA showed that "monkeypox continues to be transmitted primarily in interconnected sexual networks of gay, bisexual, or other men who have sex with men", it added. British authorities in June were recommending gay and bisexual men at higher risk of exposure to monkeypox be offered a vaccine, as the outbreak of the viral disease had gathered pace, mostly in Europe.

Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges. Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost reduction. The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their network of logistics service providers. This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising, savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the wider industry. With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral to achieving this. The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.

Health Education England (HEE) has developed funded training offers for community pharmacists, including locums aiming to become independent prescribers. Almost 3000 independent prescribing training places will be available to pharmacists from March 2023. This training enables pharmacists to support patients from diagnosis to prescribing, and to provide advice and follow-up - while also helping them to feel confident and prepared for the new challenges of their role. Courses will be available between April 2023 and March 2024, with several universities offering multiple dates for cohort intakes. Start dates will depend on the university provider. Training will enable the provision of new models of care: supporting patients from diagnosis to prescribing, providing advice and follow-up, and preparing pharmacists to provide clinical care, as pharmacy services become more widespread within emerging clinical pathways.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

HRA Pharma is celebrating the 1st anniversary of Hana, the first type of daily oral contraception available in the UK without a prescription. The launch of Hana in 2021 followed the historic decision of the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a marketing authorisation and marked a significant step forward in the women's contraception category. The company reports that pharmacists have embraced the reclassification and have found merit in using emergency contraception consultations as an opportunity to educate women on their over-the-counter contraception options. Alison Slingsby, innovations project manager at HRA Pharma, commented: "We have been delighted with Hana's reception - within weeks of launch, it quickly became the best-selling mini-pill without prescription, with more than 95 per cent market share, and has maintained this market leading position ever since. We previously had the experience of switching emergency contraceptive ellaOne to a P medicine, Hana is on track to match and eventually exceed the ellaOne volumes.

In a strategic move to enhance healthcare delivery, the NHS has announced plans to intensify the utilisation of virtual wards under the the Urgent and Emergency Care Recovery Plan. The NHS virtual wards are aimed to reduce avoidable hospital admissions across England. This follows a comprehensive analysis revealing significant benefits from virtual wards over the past year. "Virtual wards offer a transformative approach to healthcare delivery, allowing patients to receive medical care from the comfort of their own homes," remarked NHS national director for urgent and emergency care, Sarah-Jane Marsh. "This initiative not only reduces the burden on hospital resources but also ensures that patients receive timely and personalised care."

The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labelled a global health emergency by the World Health Organization. The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox. Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have been proven to help hasten recovery in those who develop the disease. The UK has over 3,000 confirmed cases of monkeypox. The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks. Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects are extensive and significant. Countless individuals in these communities do not have sufficient access to dental care, confronting a harsh reality where a minor toothache can develop into a severe problem. This situation impacts more than just oral health; it also affects general well-being, job prospects, and even self-confidence. Recent studies reveal a startling picture of dental health disparities in these areas. Studies show that individuals residing in rural areas face a higher risk of tooth loss due to untreated decay and gum disease when compared to those living in urban areas with better access to dental care. Children miss school and adults miss work due to preventable dental problems. These statistics paint a bleak portrait of a healthcare gap that demands our immediate attention. Good dental health is not a luxury; it's a fundamental component of a healthy life. It contributes to our overall well-being, playing a role in preventing chronic diseases like diabetes and heart disease. The consequences of neglecting oral health can be devastating, leading to pain, infection, and even systemic health issues.

Long waiting times for National Health Service (NHS) care are leaving people too sick to work in the UK, which is affecting the country's economy. One in three people missed work in 2022 due to delays in accessing NHS care, revealed a new survey by Pollsters Savanta. The market research consultancy surveyed 2,235 people in the UK this month on behalf of the Liberal Democrats. According to the survey results, 19 per cent of the participants could not go to work as they were waiting for a GP appointment. While 15 per cent of the respondents had to take a long period off work while they waited for treatment or surgery, 12 per cent missed work as they waited for emergency dental treatments. Overall, 36 per cent of those surveyed had missed at least some work because of difficulty getting NHS care.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.

American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022. "We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call. Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and manufacturing problems. Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.

A total of 7,599 whooping cough cases have been recorded in England from January to May 2024, according to new data released by the UK Health Security Agency (UKHSA). In January 2024, there were 555 cases, followed by 920 in February, 1,427 in March, 2,106 in April, and 2,591 in May. While the majority of cases (over 53 per cent) occurred in individuals aged 15 years or older, who typically experience milder symptoms, a significant number (262) were reported in babies under 3 months old, who are at the highest risk of severe complications and death from whooping cough. Since the outbreak began in November last year, there have been nine infant deaths (one in December 2023 and eight between January and May 2024). Whooping cough, or pertussis, is a bacterial infection affecting the lungs. This cyclical disease peaks every 3 to 5 years, with the last increase seen in 2016.

Dental care is often seen as a routine part of our healthcare regimen, but its significance cannot be overstated. The health of our teeth and gums affects not just our oral well-being but also our overall health and quality of life. This is especially true when we consider the impact of dental health on the entire family. In this blog post, we will delve into the importance of proper dental care for every member of the family and explore the benefits it brings. Understanding Dental Health Understanding dental health is fundamental to appreciating the importance of proper dental care. Professionals at newsmilelife.com explain how dental care involves a spectrum of practices dedicated to preserving the well-being of our teeth, gums, and overall oral health. This encompasses consistent brushing and flossing, regular dental examinations, professional cleanings, and addressing any dental concerns that emerge. These routines and interventions collectively contribute to a healthy mouth, preventing common dental problems and promoting optimal oral hygiene for individuals and families alike.

The Self-Care Strategy Group (SCSG) has written to Health Secretary, Wes Streeting, urging the new Labour government to fully realize self-care's benefits. With PAGB serving as the secretariat for the Group, signatories of the letter also include CPE, RPS, CCA, NPA, the Dispensing Doctors' Association, the National Association of Primary Care, the Patient Information Forum, and the Self Care Forum. The nine members highlight the importance of collaborative efforts to build an NHS fit for the future. In the letter, the group emphasises the potential of self-care to alleviate pressure on primary and emergency healthcare services. They call for expanded prescribing rights, optimised digital health tools, and streamlined referral processes between primary, diagnostic, and specialist care services.

The government has earmarked £200 million to enhance NHS resilience and expedite patient care during the upcoming winter season. This extra amount will bolster the health service during its busiest period, while protecting elective care so we can keep cutting waiting lists, Prime Minister Rishi Sunak has said. On August 13, the Prime Minister and Health and Social Care Secretary met with clinical leaders and NHS Chiefs to strategise and refine planning for urgent and emergency care, while prioritising the preservation of waiting list targets for the upcoming winter season. "Patients can be reassured that I will always back the NHS, so that those who most need help and support will get the care they need," Sunak said. "Winter is the most challenging time for the health service, which is why we've been planning for it all year - with huge government investment to fund new ambulances, beds and virtual wards." "This £200 million investment, assured by the Department of Health and Social Care as new and additional funding, should aid NHS leaders in their preparations and mitigation for what will be a seriously difficult winter period," said Matthew Taylor, Chief Executive of NHS Confederation. "The priority now is swift allocation of funding to local systems for optimal utilisation."